Compare Salesforce Inc (CRM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs BIO-TECHNE Corp — how do they compare? Salesforce Inc trades at $227.14 (market cap $184.81B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Salesforce Inc is far larger — about 16.3× BIO-TECHNE Corp's market cap, and Salesforce Inc pays the higher dividend (0.78%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and BIO-TECHNE Corp for 63 Days on average.
| CRM | TECH | |
|---|---|---|
Market Cap | $184.81B | $11.37B |
Volume | 5,173,995 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $266.23 | $72.61 |
52-Week Low | $150.12 | $43.31 |
Typical Hold Time | 89 Days | 63 Days |
Enterprise Value | $215.15B | $11.40B |
Dividend Yield | 0.78% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $224.56, down 0.19% on the day, amid a broader software sector sell-off driven by AI disruption concerns. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $5.90 vs. $3.27 expected), robust profitability (77.28% gross margin, 21.99% net margin), and healthy cash flow generation ($13.09B operating cash flow in 2025). Technical indicators remain bearish with current price near pivot point support at $224.
Outlook remains positive long-term given Salesforce's dominant market position, AI monetization growth (Agentforce ARR up 107% quarterly), and analyst consensus target of $271.91 (21% upside). Near-term risks include software sector volatility and competitive AI threats, but strong fundamentals support recovery potential from current discounted valuation levels.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
